Alto Neuroscience, Inc.
ANRO · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $104 | $556 | $529 | $529 |
| - Cash | $168 | $83 | $48 | $26 |
| + Debt | $17 | $10 | $82 | $38 |
| Enterprise Value | -$47 | $484 | $563 | $542 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | -$1 | $0 | -$0 | $0 |
| % Margin | – | – | – | 31% |
| EBITDA | -$69 | -$35 | -$27 | -$9 |
| % Margin | – | – | – | -4,305.7% |
| Net Income | -$61 | -$36 | -$28 | -$9 |
| % Margin | – | – | – | -4,374.8% |
| EPS Diluted | -2.5 | -1.35 | -1.08 | -0.36 |
| % Growth | -85.2% | -25% | -200% | – |
| Operating Cash Flow | -$47 | -$33 | -$20 | -$9 |
| Capital Expenditures | -$2 | -$0 | -$1 | -$1 |
| Free Cash Flow | -$49 | -$34 | -$21 | -$10 |